[1] MOHD S L S, ZAINAL A A, LIEW S R J, et al. The global prevalence of multidrug-resistance among acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis[J].J Infect Dis,2019,7(7):593-600. [2] HARDING C, HENNON S, FELDMAN M.Uncovering the mechanisms of acinetobacter baumannii virulence[J].Nat Rev Microbiol, 2018,1(6):91-102. [3] ZHANG Y Z, DU M M, JOHNSTON J, et al. Estimating length of stay and inpatient charges attributable to hospital-acquired bloodstream infections[J]. Antimicrob Resist Infect Control Actions,2020,9(1):137. [4] OZYURT S, KOSTAKOGLU U, YILDIZ I, et al. Investigation of the clonal associations in acinetobacter baumannii strains isolated from the respiratory samples of patients in a tertiary research hospital[J].Niger J Clin Pract, 2020,23(11):55-62. [5] 潘楚芝, 李裕军, 赵子文,等. 纸片扩散法与微量肉汤稀释法检测鲍曼不动杆菌对替加环素体外敏感性的比较[J]. 广东医学,2013,14(1):19-21. [6] LI Y J, PAN C Z, FANG C Q,et al. Pneumonia caused by extensive drug-resistant acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality[J]. BMC Infect Dis, 2017,17(3):71. [7] ABDALLAH M, ALSALEH H, BARADWAN A, et al. Intraventricular tigecycline as a last resort therapy in a patient with difficult-to-treat healthcare-associated acinetobacter baumannii ventriculitis: a case report[J]. SNCCM,2020:1-5. [8] FU Y, ZHOU J, ZHOU H, et al. Wide dissemination of oxa-23-producing carbapenem-resistant acinetobacter baumannii clonal complex 22 in multiple cities of China[J].J Antimicrob Chemother, 2010,65(6):44-50. [9] RUAN Z, CHEN Y, JIANG Y, et al. Wide distribution of CC92 carbapenem-resistant and oxa-23-producing acinetobacter baumannii in multiple provinces of China[J]. Int J Antimicrob, 2013,42(32):2-8. [10] ZHONG Q, XU W, WU Y, et al. Clonal spread of carbapenem non-susceptible acinetobacter baumannii in an intensive care unit in a teaching hospital in China[J].Ann Lab Med,2012,32(41):3-9. [11] HE C, XIE Y, ZHANG L, et al. Increasing imipenem resistance and dissemination of the isaba1-associated blaoxa-23 gene among acinetobacter baumannii isolates in an intensive care unit[J].Int J Med Microbiol,2011,60(3):37-41. [12] LI Y, PAN C, ZHAO Z, et al. Effects of a combination of amlodipine and imipenem on 42 clinical isolates of acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China[J]. BMC Infect Dis, 2013,1(3):548. [13] 李裕军, 潘楚芝, 赵子文,等. 鲍曼不动杆菌多位点序列分型与抗生素耐药表型的关系[J]. 广东医学, 2015,12(18):18-21. [14] ZHOU Y, WU X, ZHANG X, et al. Genetic characterization of ST195 and ST365 carbapenem-resistant acinetobacter baumannii harboring blaoxa-23 in Guangzhou, China[J]. Microb Drug Resist(Larchmont, NY),2015,21(3):86-90. [15] BARTUAL S G, SEIFERT H, HIPPLER C,et al. Development of a multilocus sequence typing scheme for characterization of clinical isolates of acinetobacter baumannii[J]. J Clin Microbiol, 2005,43(43):82-90. [16] Acinetobacter baumannii mlst databases. http://pubmlst.org/abaumannii/.Accessed 22 Mar 2017. 2017. [17] eBURSTv3 algorithm. http://eburst.mlst.net/.Accessed3Mar2018.2018. [18] 苏运钦,叶聪秀,车玉传,等. 多位点序列分型技术在鲍曼不动杆菌同源性分析中的应用[J]. 中国抗生素杂志,2013,38(5):360-362. [19] 刘丽娟,陈金之,张志军,等. 院内多重耐药鲍曼不动杆菌分子流行病学特征研究[J]. 中国抗生素杂志,2019,44(4):478-482. [20] 刘舒雅,赵雷,叶英. 安徽地区耐碳青霉烯鲍曼不动杆菌分子流行病学研究[J]. 中国抗生素杂志,2018,43(9):1151-1155. [21] 林云万,周勇,张旭,等. 广州市ICU环境中耐碳青霉烯类鲍曼不动杆菌的克隆相关性[J]. 中国感染控制杂志,2018,17(4):294-298. [22] YING J, LU J W, ZONG L, et al. Molecular epidemiology and characterization of genotypes of acinetobacter baumannii isolates from regions of south China[J]. Jpn J Infect Dis, 2016,69(3):180-185. [23] LOWINGS M, EHLERS M M, DREYER A W, et al. High prevalence of oxacillinases in clinical multidrug-resistant acinetobacter baumannii isolates from the tshwane region, South Africa - an update[J]. BMC Infect Dis,2015,15(5):21. |